for Journals by Title or ISSN
for Articles by Keywords
help
Journal Cover The Lancet Oncology
  [SJR: 13.94]   [H-I: 197]   [142 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1470-2045 - ISSN (Online) 1474-5488
   Published by Elsevier Homepage  [3043 journals]
  • Is it time to convert the frequency of radiotherapy in small-cell lung
           cancer'
    • Authors: Haiyan Zeng; Jinming Yu; Shuanghu Yuan
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Haiyan Zeng, Jinming Yu, Shuanghu Yuan


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30580-6
       
  • Is it time to convert the frequency of radiotherapy in small-cell lung
           cancer'
    • Authors: Timur Mitin; Matthew Farrell; John Holland; Jeremy Cetnar; Charles R Thomas
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Timur Mitin, Matthew Farrell, John Holland, Jeremy Cetnar, Charles R Thomas


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30581-8
       
  • Is it time to convert the frequency of radiotherapy in small-cell lung
           cancer'
    • Authors: Chukwuka Eze; Olarn Roengvoraphoj; Maurice Dantes; Farkhad Manapov
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Chukwuka Eze, Olarn Roengvoraphoj, Maurice Dantes, Farkhad Manapov


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30620-4
       
  • Is it time to convert the frequency of radiotherapy in small-cell lung
           cancer' – Authors' reply
    • Authors: Corinne Faivre-Finn; W David Ryder; Fiona Blackhall
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Corinne Faivre-Finn, W David Ryder, Fiona Blackhall


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30611-3
       
  • Rituximab and autologous stem-cell transplantation for high-risk diffuse
           large B-cell lymphoma
    • Authors: Tetsuya Tanimoto; Kumi Oshima; Kenji Tsuda; Jinichi Mori; Hiroaki Shimmura
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Tetsuya Tanimoto, Kumi Oshima, Kenji Tsuda, Jinichi Mori, Hiroaki Shimmura


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30706-4
       
  • Rituximab and autologous stem-cell transplantation for high-risk diffuse
           large B-cell lymphoma – Authors' reply
    • Authors: Annalisa Chiappella; Maurizio Martelli; Andrea Evangelista; Umberto Vitolo
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Annalisa Chiappella, Maurizio Martelli, Andrea Evangelista, Umberto Vitolo


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30702-7
       
  • SRS versus WBRT for resected brain metastases
    • Authors: Jinbo Yue; Jinming Yu
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Jinbo Yue, Jinming Yu


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30642-3
       
  • SRS versus WBRT for resected brain metastases – Authors' reply
    • Authors: David Roberge; Paul Brown
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): David Roberge, Paul Brown


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30703-9
       
  • Finding gold in tumour immunotherapy
    • Authors: Howard L Kaufman
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Howard L Kaufman


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30699-x
       
  • Labetuzumab govitecan in metastatic colorectal cancer
    • Authors: Manjulika Das
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Manjulika Das


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30664-2
       
  • Pazopanib for advanced liposarcoma
    • Authors: Judith A Gilbert
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Judith A Gilbert


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30663-0
       
  • Discontinuation of melanoma combination immunotherapy
    • Authors: Holly Baker
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Holly Baker


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30668-x
       
  • Tax on tobacco and sugary drinks in the United Arab Emirates
    • Authors: Talha Khan Burki
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Talha Khan Burki


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30669-1
       
  • Androgen deprivation therapy for prostate cancer
    • Authors: Manjulika Das
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Manjulika Das


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30670-8
       
  • Access to opioids: a balance of harms
    • Authors: The Lancet Oncology
      First page: 1285
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): The Lancet Oncology


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30704-0
       
  • Guadecitabine: a new therapeutic option for acute myeloid leukaemia'
    • Authors: Felicetto Ferrara
      Pages: 1287 - 1288
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Felicetto Ferrara


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30614-9
       
  • Carfilzomib versus bortezomib: no longer an ENDEAVOR
    • Authors: Niels WCJ van de Donk
      Pages: 1288 - 1290
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Niels WCJ van de Donk


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30613-7
       
  • Defeating anaemia in myelodysplastic syndromes: another step forward
    • Authors: Valeria Santini
      Pages: 1290 - 1292
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Valeria Santini


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30671-x
       
  • Nodal status and survival in anal cancer
    • Authors: Rodrigo Oliva Perez; Guilherme Pagin São Julião; Bruna Borba Vailati
      Pages: 1292 - 1293
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Rodrigo Oliva Perez, Guilherme Pagin São Julião, Bruna Borba Vailati


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30587-9
       
  • Targeting PI3K/AKT pathway in triple-negative breast cancer
    • Authors: Suzette Delaloge; Louise DeForceville
      Pages: 1293 - 1294
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Suzette Delaloge, Louise DeForceville


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30514-4
       
  • ACT IV: the final act for rindopepimut'
    • Authors: Elizabeth R Gerstner
      Pages: 1294 - 1296
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Elizabeth R Gerstner


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30619-8
       
  • miR-16: expanding the range of molecular targets in mesothelioma
    • Authors: Dean Fennell
      Pages: 1296 - 1297
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Dean Fennell


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30596-x
       
  • Maintaining quality of life for patients with neuroendocrine tumours
    • Authors: Thomas Walter
      Pages: 1299 - 1300
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Thomas Walter


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30618-6
       
  • Cancer in Peru: a detailed examination
    • Authors: Cassandra Coburn; David Collingridge
      Pages: 1300 - 1301
      Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10
      Author(s): Cassandra Coburn, David Collingridge


      PubDate: 2017-09-28T15:19:19Z
      DOI: 10.1016/s1470-2045(17)30711-8
       
  • Copanlisib in heavily pretreated indolent lymphoma
    • Authors: Manjulika Das
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Manjulika Das


      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30783-0
       
  • First-line obinutuzumab for follicular lymphoma
    • Authors: Holly Baker
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Holly Baker


      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30781-7
       
  • Adjuvant zoledronic acid to treat breast cancer: not for all
    • Authors: Luís Costa; Arlindo R Ferreira
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Luís Costa, Arlindo R Ferreira


      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30695-2
       
  • Effect of MAF amplification on treatment outcomes with adjuvant zoledronic
           acid in early breast cancer: a secondary analysis of the international,
           open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial
    • Authors: Robert Coleman; Andrew Hall; Joan Albanell; Andrew Hanby; Richard Bell; David Cameron; David Dodwell; Helen Marshall; Joël Jean-Mairet; Juan-Carlos Tercero; Federico Rojo; Walter Gregory; Roger R Gomis
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Joël Jean-Mairet, Juan-Carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis
      Background Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid. Methods The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples. Patients were randomly assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledronic acid every 3–4 weeks for six doses, then every 3–6 months until the end of 5 years. Minimisation took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and treating centre. The primary endpoint was disease-free survival; the secondary endpoint, invasive-disease-free survival, was the primary disease endpoint for the analysis in this report. MAF amplification was assessed by fluorescence in-situ hybridisation of two cores of breast tumour tissue in a microarray, done in a central laboratory by technicians unaware of treatment assignment. We used multivariate analyses to assess disease outcomes by intention to treat. We also assessed interactions between MAF-positive status and menopausal status on efficacy of zoledronic acid. The AZURE trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN79831382. Findings 1739 AZURE patients contributed primary tumour samples, of whom 865 (50%) had two assessable cores (445 in the control groups and 420 in the zoledronic acid group). 184 (21%) tumours were MAF positive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MAF negative. At a median follow-up of 84·6 months (IQR 72·0–95·8), MAF status was not prognostic for invasive-disease-free survival in the control group (MAF-positive vs MAF-negative: hazard ratio [HR] 0·92, 95% CI 0·59–1·41), but was in the zoledronic acid group (0·52, 0·36–0·75). In patients with MAF-negative tumours, zoledronic acid was associated with higher invasive-disease-free survival than was control treatment (HR 0·74, 95% CI 0·56–0·98), but not in patients who had MAF-positive tumours. Additionally, among 121 patients not postmenopausal at randomisation with MAF-positive tumours, zoledronic acid was associated with lower invasive-disease-free survival (HR 2·47, 95% CI 1·23–4·97) and overall survival (2·27, 95% CI 1·04–4·93) than control treatment. Interpretation MAF status can predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a potential companion diagnostic. Funding Novartis Global and Inbiomotion.

      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30603-4
       
  • Oncolytic virus therapy in advanced melanoma
    • Authors: Elizabeth Gourd
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Elizabeth Gourd


      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30782-9
       
  • Antibody-drug conjugates: can the payload improve activity in HER2
           expressing cancers'
    • Authors: Manish A Shah
      Abstract: Publication date: Available online 13 October 2017
      Source:The Lancet Oncology
      Author(s): Manish A Shah


      PubDate: 2017-10-14T14:06:42Z
      DOI: 10.1016/s1470-2045(17)30720-9
       
  • Extended adjuvant aromatase inhibition after sequential endocrine therapy
           (DATA): a randomised, phase 3 trial
    • Authors: Vivianne Tjan-Heijnen; Irene van Hellemond Petronella Peer Astrid Swinkels Carolien
      Abstract: Publication date: Available online 12 October 2017
      Source:The Lancet Oncology
      Author(s): Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Maaike de Boer, Wilfred K de Roos, Sabine C Linn, Alexander L T Imholz, Caroline M Seynaeve
      Background The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment period still needs clarification. To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen. Methods DATA was a prospective, randomised, open-label, multicentre, phase 3 study done in 79 hospitals in the Netherlands. We randomly assigned postmenopausal women with hormone receptor-positive early breast cancer with no signs of disease recurrence after 2–3 years of adjuvant tamoxifen to either 3 or 6 years of anastrozole treatment (1 mg orally once a day) in a 1:1 ratio. We used TENALEA (Trans European Network for Clinical Trials Services) for the randomisation procedure. Stratification factors were nodal status, hormone receptor status, HER2 status, and tamoxifen treatment duration. The primary study endpoint of this analysis was disease-free survival starting beyond 3 years after randomisation (adapted disease-free survival). Here we report the final analysis from the DATA trial, which is registered with ClinicalTrials.gov, number NCT00301457. Findings Between June 28, 2006, and Aug 10, 2009, we screened 1912 patients of whom 955 were assigned to the 3-year group and 957 to the 6-year anastrozole treatment group. 1860 patients were eligible (931 in the 6-year group and 929 in the 3-year group) and 1660 were disease free 3 years after randomisation. The 5-year adapted disease-free survival was 83·1% (95% CI 80·0–86·3) in the 6-year group and 79·4% (76·1–82·8) in the 3-year group (hazard ratio [HR] 0·79 [95% CI 0·62–1·02]; p=0·066). Patients in the 6-year treatment group had more adverse events than those in the 3-year treatment group, including all-grade arthralgia or myalgia (478 [58%] of 827 in the 6-year treatment group vs 438 [53%] of 833 in the 3-year treatment group) and osteopenia or osteoporosis (173 [21%] vs 137 [16%]). Interpretation We cannot recommend the use of extended adjuvant aromatase inhibition after 5 years of sequential endocrine therapy in all postmenopausal women with hormone receptor-positive breast cancer. Funding AstraZeneca.

      PubDate: 2017-10-13T08:51:05Z
       
  • Extended adjuvant therapy: the role of subset analyses
    • Authors: Kathleen I Pritchard
      Abstract: Publication date: Available online 12 October 2017
      Source:The Lancet Oncology
      Author(s): Kathleen I Pritchard


      PubDate: 2017-10-13T08:51:05Z
      DOI: 10.1016/s1470-2045(17)30787-8
       
  • Moving toward a precision medicine approach in metastatic
           castration-resistant prostate cancer
    • Authors: Rahul Aggarwal
      Abstract: Publication date: Available online 9 October 2017
      Source:The Lancet Oncology
      Author(s): Rahul Aggarwal


      PubDate: 2017-10-13T08:51:05Z
      DOI: 10.1016/s1470-2045(17)30718-0
       
  • PD-1 inhibition in bone sarcoma and soft-tissue sarcoma
    • Authors: Olivier Mir; Charles Julien Adam
      Abstract: Publication date: Available online 4 October 2017
      Source:The Lancet Oncology
      Author(s): Olivier Mir, Charles Honoré, Julien Adam


      PubDate: 2017-10-05T13:22:22Z
       
  • Is competition bad for our health(care)' We simply don't know
    • Authors: Kalipso Chalkidou
      Abstract: Publication date: Available online 3 October 2017
      Source:The Lancet Oncology
      Author(s): Kalipso Chalkidou


      PubDate: 2017-10-05T13:22:22Z
      DOI: 10.1016/s1470-2045(17)30623-x
       
  • Correction to Lancet Oncol 2017; 18: 1327–37
    • Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10


      PubDate: 2017-09-28T15:19:19Z
       
  • Correction to Lancet Oncol 2017; 18: 1338–47
    • Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10


      PubDate: 2017-09-28T15:19:19Z
       
  • Correction to Lancet Oncol 2017; 18: e564
    • Abstract: Publication date: October 2017
      Source:The Lancet Oncology, Volume 18, Issue 10


      PubDate: 2017-09-28T15:19:19Z
       
  • Immune response boosted in metastatic colorectal cancer
    • Authors: Elizabeth Gourd
      Abstract: Publication date: Available online 14 September 2017
      Source:The Lancet Oncology
      Author(s): Elizabeth Gourd


      PubDate: 2017-09-15T15:04:05Z
      DOI: 10.1016/s1470-2045(17)30712-x
       
  • ESMO 2017 Congress
    • Authors: Katherine Gourd
      Abstract: Publication date: Available online 14 September 2017
      Source:The Lancet Oncology
      Author(s): Katherine Gourd


      PubDate: 2017-09-15T15:04:05Z
      DOI: 10.1016/s1470-2045(17)30713-1
       
  • BRAFV600E and BRAF-inactivating mutations in NSCLC
    • Authors: Rafael Rosell; Niki Karachaliou
      Abstract: Publication date: Available online 11 September 2017
      Source:The Lancet Oncology
      Author(s): Rafael Rosell, Niki Karachaliou


      PubDate: 2017-09-15T15:04:05Z
      DOI: 10.1016/s1470-2045(17)30678-2
       
  • Thalidomide reduces chemotherapy-induced vomiting
    • Authors: Elizabeth Gourd
      Abstract: Publication date: Available online 8 September 2017
      Source:The Lancet Oncology
      Author(s): Elizabeth Gourd


      PubDate: 2017-09-10T16:42:10Z
      DOI: 10.1016/s1470-2045(17)30676-9
       
  • Eribulin: an effective therapeutic option in liposarcoma
    • Authors: Manjulika Das
      Abstract: Publication date: Available online 8 September 2017
      Source:The Lancet Oncology
      Author(s): Manjulika Das


      PubDate: 2017-09-10T16:42:10Z
      DOI: 10.1016/s1470-2045(17)30675-7
       
  • Use of cancer-related emergency departments
    • Authors: Talha Khan Burki
      Abstract: Publication date: Available online 8 September 2017
      Source:The Lancet Oncology
      Author(s): Talha Khan Burki


      PubDate: 2017-09-10T16:42:10Z
      DOI: 10.1016/s1470-2045(17)30673-3
       
  • E-cigarette use in young people in the UK
    • Authors: Priya Venkatesan
      Abstract: Publication date: Available online 8 September 2017
      Source:The Lancet Oncology
      Author(s): Priya Venkatesan


      PubDate: 2017-09-10T16:42:10Z
      DOI: 10.1016/s1470-2045(17)30674-5
       
  • GeDDiS: insight into frontline therapy in soft tissue sarcoma
    • Authors: William D Tap
      Abstract: Publication date: Available online 4 September 2017
      Source:The Lancet Oncology
      Author(s): William D Tap


      PubDate: 2017-09-05T11:20:23Z
      DOI: 10.1016/s1470-2045(17)30672-1
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.167.250.64
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016